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Abstract:  Background: Micronutrient supplementation has been shown to reduce the 
progression of HIV but does not have an effect on the intestinal barrier or the intestinal 
microbiota of HIV patients. Studies have suggested that probiotics could potentially 
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complement micronutrients in preserving the immune-function of HIV patients. Objective: 
Assess the impact of micronutrient supplemented probiotic yogurt on the immune function 
of HIV patients. Design: We performed a randomized, double blind, controlled trial with 
CD4 count as primary outcome among HIV patients naïve to anti-retroviral treatment. 
Secondary outcomes included hematological parameters, incidence of diarrhea and clinical 
symptoms. A total of 112 HIV patients were randomized to receive a micronutrient 
fortified yogurt with (n = 55) or without additional probiotic Lactobacillus rhamnosus  
GR-1 (n = 57) for four weeks. Results: An average decline in CD4 count of −70 cells/μL 
(95% CI: −154 to −15) was observed in the micronutrient, probiotic group versus a 
decrease of −63 cells/μL (95% CI: −157 to −30) in the micronutrient control group   
(p = 0.9). Additional probiotic supplementation was well tolerated and not associated with 
adverse events. No difference between groups was detected in incidence of diarrhea or 
clinical symptoms. An improvement of hemoglobin levels was observed for all subjects, 
based upon a mean difference from baseline of 1.4 g/L (SD = 6) (p = 0.02). Conclusion: 
The addition of probiotics to a micronutrient fortified yogurt was well tolerated by HIV 
patients but was not associated with a further increase in CD4 count after one month. 
Keywords: micronutrients; probiotics; HIV; Lactobacillus; immune system 
 
1. Introduction  
Poor nutritional status among people living with HIV is a common problem [1] and has been 
associated with enhanced HIV progression in numerous observational studies [2,3]. Impaired immune 
function of people living with HIV is further compounded by a deleterious impact of the virus on the 
gut-associated mucosal immune system [4,5], which presumably results in translocation of microbial 
products from the intestinal tract [6,7], an aberrant intestinal microbiota [8,9], and an increased incidence 
of intestinal infections [10]. Microbial translocation as a result of impaired gut barrier function, in 
combination with low micronutrient levels, may further enhance the progression of HIV [6,11,12]. 
Supplementation of micronutrients, most notably B-complex, vitamin C and E, can reduce the 
progression and mortality of HIV [13–17], but does not impact intestinal barrier impairment [18]. 
Supplementation of vitamin A as single supplement does not appear to reduce the progression of HIV 
or mortality related to the disease in adults [15,19]. 
Probiotics, defined as “live microorganisms which, when administered in adequate amounts, confer 
a health benefit on the host” [20], have been used with some success to preserve the immune-function 
of people living with HIV in the following studies. A small randomized controlled trial (RCT) was 
performed in Brazil among 77 children infected with HIV. Half of the children received a supplement 
with probiotic strain Bifidobacterium bifidum and Streptococcus thermophilus for two months. After 
the two month period, CD4 counts among the treatment group increased 118 cells/μL  versus  a 
decrease of 42 cells/μL among the placebo group (p = 0.05) [21]. Another small pilot RCT in Nigeria 
discovered a small, but statistically significant effect, of four weeks of Lactobacillus rhamonus GR-1 
and Lactobacillus reuteri RC-14 supplementation on the CD4 count of 24 HIV infected women. The Nutrients 2011, 3 
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treatment group showed an increase in CD4 of 6.7 cells/μL compared to a decrease of 2.2 cells/μL in 
the control group (p = 0.05) [22]. Lastly, an observational study in Tanzania found that yogurt 
supplemented with Lactobacillus rhamnosus GR-1 increased the CD4 count with 0.28 cells/μL/day  
(p = 0.003) among HIV infected men and women in Tanzania [23]. The mechanisms are believed to 
involve enhancing the gut barrier function [24,25], alleviating systemic inflammation [26,27], or 
reducing the duration of gastro-intestinal infections [28] (reviewed in [29]).  
Despite massive efforts, only one out of three people in need of anti-retroviral treatment (ART) 
currently have access to the treatment [30]. The application of a food-based intervention, targeting 
both micronutrient deficiencies and an impaired gut-associated mucosal immune system, could   
provide an optimal adjunctive intervention to potentially delay the progression of HIV. Since 2005, a 
small community kitchen in Tanzania has produced yogurt supplemented with probiotics using   
Lactobacillus rhamnosus GR-1 [31]. We initiated a randomized, double-blind, placebo controlled 
study to assess whether the addition of probiotic L. rhamnosus GR-1 to a micronutrient fortified yogurt 
could positively impact the immune function of HIV patients. We selected L. rhamnosus GR-1 for its 
potential to reduce the translocation of Salmonella typhimurium from the gut to distant organs, as 
assessed in a mouse model [32], reduce systemic inflammation in a population with inflammatory 
bowel disease [33], and to increase the CD4 count in an HIV infected population [23]. 
2. Experimental Section  
2.1. Study Design 
The primary outcome was the mean change of CD4 count from baseline to 4 weeks follow-up. 
Secondary outcomes included hematology indicators (creatinine, albumin, alanine transaminase (ALT), 
and full blood count), incidence of diarrheal episodes, symptoms, physical energy and their ability to 
perform activities of daily living. Inclusion criteria were; confirmed HIV infection, naïve to ART and 
not eligible for ART initiation (i.e., CD4 count ≥200 with WHO stage I or II infection or CD4 count 
≥350 and CDC stage III infection [34]), ability to attend the clinic every other day, ≥18 years of age, not 
pregnant or lactating, and with no known lactose intolerance or milk allergy. We calculated a sample 
size of 49 per treatment arm to detect a within person difference of 15 cells/μL in CD4 count between 
the groups with a power of 90%. The calculation assumed an attrition rate of 25% and a standard 
deviation of 20 cells/μL within-person change in CD4 count. The Medical Research Coordinating 
Committee of the National Institute for Medical Research, Tanzania, approved the study design and 
protocol. Participants were informed of the purpose of the trial and gave their signed or thumb printed 
informed consent before participation. All study procedures were in concordance with the declaration 
of Helsinki of 1975, as revised in 2008.  
2.2. Study Subjects and Data Collection 
Recruitment took place at Shaloom health centre and at Sekou-Toure Regional Hospital, Mwanza, 
Tanzania from June to July 2008. Randomization and follow-up were conducted at Sekou-Toure 
regional hospital and extended until August 2008. During the baseline visit, a physical examination was 
performed by a physician, blood was taken to perform biochemical and hematological measurements Nutrients 2011, 3 
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and a structured interview was performed on demographics, medical history, and physical energy 
levels. The participants recorded the occurrence of diarrheal episodes using a diary, which was collected 
at each visit. Diarrhea was defined as three or more loose or watery stools in a 24-h period [35].  
Participants were randomized to receive a yogurt that was fortified solely with micronutrients 
(control group) or was fortified with both micronutrients and L. rhamnosus GR-1 (probiotic group) for 
4  weeks. Both yogurts were indistinguishable in taste or appearance. Subjects were consecutively 
assigned to one of the two treatment codes according to a computer generated schedule in blocks of 10. 
The batches of yogurt were coded by a researcher not involved with data collection to ensure that 
neither the researchers nor the subjects were aware of their treatment assignments. Participants were 
asked to return to the clinic every other day to receive a two-day supply of yogurt of which one portion 
was consumed in the clinic to ensure at least 50% adherence. Subjects returned after 4 weeks for the 
follow-up visit and were encouraged throughout the duration of the study to report any adverse events 
or changes in their condition. The procedures of the baseline visit were repeated exactly at the follow-up 
visit, with additional questions on adverse events. Participants who did not arrive at their follow-up 
visit were contacted by phone. 
2.3. Intervention 
The nutrient premix blend was provided by Fortitech Strategic Nutrition (Schenectady, New York, 
NY, USA), for which the concentrations of nutrients per portion of yogurt (125 mL) are summarized  
in Table 1. We based the formulation on that described by Kaiser et al. [17], but reduced the 
concentrations of the micronutrients to acceptable physiological levels that were also compatible with 
inclusion into yogurt. Preparation of the probiotic stock culture took place at National Institute for 
Medical Research (NIMR), Mwanza, and the organism was added to yogurt produced by a trained 
group of local women. The viability and abundance of the probiotic strain in the yogurt was assured 
for every batch using procedures previously described [36]. Overall, a mean 1.23 × 10
9 colony forming 
units/mL of L. rhamnosus GR-1 was found in the probiotic yogurt resulting in an intended dose of  
15.38 × 10
10 colony forming units/day. 
2.4. Laboratory Measurements 
The laboratory measurements were performed at the NIMR, according to good laboratory practices. 
At baseline and at 4 weeks the CD4 count was measured using the Partec FACS (Partec GmbH, 
Münster, Germany), hematological parameters were measured using the Beckman Coulter AcT5 Diff 
Al (Beckman Coulter, Brea, CA, USA) and biochemistry parameters using the Synchron CX
®4 PRO 
(Beckman Coulter, Brea, CA, USA).  
2.5. Analyses 
All analyses were performed on an intent-to-treat basis. The plan of data analysis was clearly 
established and stated in the study protocol before start of the study. Normally-distributed continuous 
(CD4 count, hematology parameters) data were compared using within-subject differences from 
baseline to follow-up, and tested using an unpaired students t-test. To assess the effect of the CD4 Nutrients 2011, 3 
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count, HIV symptoms, BMI and anemia at baseline on the treatment response, a linear regression 
model was fitted. Categorical data (baseline characteristics) were compared using a χ
2 test. All tests 
were performed two-sided at the α = 0.05 level with no adjustments made for multiple comparisons. 
Compliance with the study treatment was calculated as the number of days the participant consumed 
the yogurt divided by the total number of days the yogurt should have been consumed. Data was stored 
in an Access database and analyzed using SPSS 15.0 software. 
Table 1. Probiotic and micronutrient content of the yogurts. 
Ingredient Amount/125  g 
Lactobacillus rhamnosus GR-1 *  10
9 CFU/mL 
Vitamin A (as Beta carotene and Palmitate)  1500 IU 
Vitamin E (as acetate)  5.7 IU 
Niacinamide  3.8 mg 
Vitamin B1 (thiamin)  0.3 mg 
Vitamin B12 (cyanocobalamin)  0.6 μg 
Vitamin B6 (pyroxine)  0.3 mg 
Vitamin C (ascorbic acid)  21 mg 
Iron (as ferric pyrophosphate)  3.3 mg 
Selenium (sodium selenite)  13.8 μg 
Zinc (zinc sulphate)  2.4 mg 
DHA (omega-3 from fish oil)  13 mg 
EPA (omega-3 from fish oil)  19 mg 
CFU = Colony forming units; * Only in probiotic-supplemented yogurt. 
3. Results  
3.1. Baseline Characteristics  
A total of 148 patients were screened for participation and 112 patients were enrolled. After 
randomization one participant in the control group was diagnosed with Kaposi’s sarcoma and excluded 
from analyses according to exclusion criteria, as this indicated that a WHO stage IV had been present 
at baseline. Of 55 participants in the probiotic group, 52 completed follow-up versus all 56 participants 
in the control group (p = 0.1) (Figure 1). At baseline, 21 out of 53 (40%) in the probiotic group had 
HIV-related symptoms upon physical examination (oral thrush, oral ulcers or maculo-papular rash), 
compared to 12 out of 55 (21%) in the control group (p = 0.03). There was no difference in the median 
time living with HIV between the probiotic group (791 days, range 57–3511) and the placebo group 
(584 days, range 31–3458) (Wilcoxon rank test, p = 0.2). Other baseline characteristics were 
comparable between the groups (Table 2). Overall, 92 out of 109 (84%) participants had low serum 
albumin (≤36 g/L) and 43 out of 97 tested (44%) had anemia at baseline (hemoglobin ≤110 g/L)  
(Table 3). Compliance was excellent, among the probiotic group the product was consumed at a mean  
98% (95% CI: 97–100) of days required compared to 96% (95% CI: 93–100) among the control   
group (p = 0.2).  Nutrients 2011, 3 
 
 
902
Figure 1. Trial profile. 
 
a Due to travelling; 
b Stage 4 HIV-infection: Karposi’s sarcoma. 
Table 2. Baseline characteristics of the treatment groups. In a few cases, data were   
not obtained.  
Characteristic 
a Reference  Probiotics 
n = 55  
Control 
n = 56  
P 
Gender female    47 (86%)  48 (86%)  1.0 
Age (years)  <30  10 (19%)  8 (15%)  0.6 
  ≥30  44 (81%)  46 (85%)   
Water source  Pipe  45 (83%)  41 (73%)  0.2 
  Well  9 (17%)  15 (27%)   
Working ability  Unable  5 (10%)  5 (9%)  1.0 
  Able  47 (90%)  51 (91%)   
Marital status 
b  Widow  18 (33%)  24 (43%)  0.8 
  Divorced  12 (22%)  16 (28%)   
  Married  19 (34%)  15 (27%)   
  Single  6 (11%)  1 (2%)   
Diagnosed with HIV 
(years) 
<1 
18 (33%)  22 (39%) 
0.5 
  ≥1  37 (67%)  34 (61%)   
CD4 Count (cells/mm
3)  <350  26 (47%)  30 (54%)  0.5 
  351–500  12 (22%)  14 (25%)   
  ≥501  17 (31%)  12 (21%)   
WHO disease stage 
b  1  39 (75%)  45 (80%)  0.5 
  2  5 (10%)  4 (7%)   
  3  8 (15%)  7 (13%)   
Any HIV related symptom 
c    21 (38%)  12 (21%)  0.03 Nutrients 2011, 3 
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Table 2. Cont. 
BMI <18.5  kg/m
2  1 (2%)  6 (11%)  0.1 
Anemia (Hemoglobin)  <110 g/L  22 (40%)
d 21  (38%)  0.6 
Hypoalbuminemia (Albumin)  <36 g/L  43 (78%)
e 49  (88%)  0.4 
Clotrimoxazole use    16 (29%)  12 (21%)  0.4 
Vitamin B complex use    6 (11%)  4 (7%)  0.5 
BMI = Body Mass Index. 
a The following categories have missing values: Age (3), water source (1), 
Functional Status (3), BMI (4), WHO disease stage (3), Any HIV related symptom (3). 
b The 
following subgroups were combined for valid testing: Marital status: “Widow” with “divorced” 
with “single”; WHO disease stage: stage “2” with “3”; 
c Any HIV related symptom = oral thrush, 
oral ulcers or maculo-papular rash on physical examination. As not all data could be obtained, 
some of the calculations in the table are not for the full 55 or 56 participatants; 
d there were missing 
biological samples for 8 of the participants at baseline in the probiotic group, i.e., 22 of 47 showed 
low hemoglobin levels in the probiotic group; 
e there were two missing samples for albumin in the 
probiotic group.  
Table 3. Changes in hematology and biochemistry parameters from baseline to follow-up. 
   Probiotics    Control   
Parameter
  Reference 
Value/unit 
Base 
a 
n/total 
FU 
n/total
% Change 
b
mean ± SD 
Base 
n/total
FU 
n/total 
% Change
mean ± SD
 
p 
c 
Creatinine  ≥139 μmol/L 1/52  0/50  −1 ± 17  0/56  1/56  1 ± 29  0.6 
Albumin  <36 g/L  43/53  46/50  0 ± 20  49/56  51/56  −1 ± 24  0.9 
ALT  ≥50 IU/L  2/53  2/50  −3 ± 9  2/56  1/56  1 ± 10  0.1 
Hemoglobin <110  g/L 22/47  19/43 −9 ± 53  21/50  17/47  4 ± 53  0.3 
Platelets  <150 × 10
9/L 3/47  3/43  −13 ± 47  4/50  4/47  −5 ± 23  0.3 
RBC  <4 × 10
12/L 29/47  17/43  −10 ± 53  33/50  14/47  −6 ± 66  0.7 
WBC  ≥11 × 10
9/L 0/48 0/43  −1 ± 18  1/50  0/47  −7 ± 21  0.2 
Neutrophils  ≥80% 0/44  0/37  −6 ± 38  0/46  0/45  −12 ± 72  0.6 
Lymphocytes  ≥50% 13/47  13/43  −6 ± 36  11/50  14/47  10 ± 72  0.2 
Monocytes  ≥10%  0/47  0/43  1 ± 12  0/50  0/47  −1 ± 15  0.6 
Eosinophils  ≥5% 23/44  19/37  −7 ± 16  26/46  28/45  −1 ± 12  0.1 
Basophils  ≥2% 0/47  0/43  −2 ± 4  0/50  0/47  −1 ± 4  0.1 
Base = Baseline; FU = Follow-up; SD = Standard Deviation; ALT = Alanine transaminase;   
RBC = Red blood cells; WBC = White blood cells; 
a Number of participants above or below 
reference value; 
b Mean within-subject change from baseline to follow-up; 
c Tested using   
within-subject change from baseline to follow-up.  
3.2. Primary Outcome 
The probiotic group experienced an average decline of −70 cells/μL (95% CI: −154 to −15 cells/μL) 
CD4 cells from baseline versus a decline of −63 cells/μL (95% CI: −157 to −30) in the control   
group (p = 0.9). Adjusting for baseline CD4 count, HIV symptoms, BMI or anemia yielded similar 
results and did not change this finding. The baseline CD4 count was highly predictive of the 
development of the CD4 count during follow-up. Overall, those with a CD4 count of 200–350 
experienced an increase in CD4 count of 67 cells/μL (95% CI: −19 to 152) during follow-up. This in Nutrients 2011, 3 
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contrast to those with a CD4 count of ≥350 cells/μL at baseline who experience an average decline of 
187 cells/μL (95% CI: −372 to −136) during follow-up. Among those with a CD4 count of   
200–350 cells/μL, HIV related symptoms were more common (21/53) than those with a CD4 count of 
≥350 cells/μL (12/55) (p = 0.05). No differences were detected in the number of days living with HIV 
between those with a CD4 count of 200–350 or ≥350 cells/μL at baseline. 
3.3. Secondary Outcomes 
No differences were found in self-reported symptoms (mouth ulcers, coughing, fever, nausea, and 
stomach pain), self-reported physical energy level or ability to perform daily activities following the 
one month treatment. Among the probiotic group, 13 out of 51 (26%) participants experienced diarrhea 
for at least one day during the intervention, which was not different from the control group, where 16 out 
of 54 (30%) experienced diarrhea (p = 0.6). Overall, an improvement of hemoglobin levels was 
observed with a mean difference from baseline of 1.4 g/L (SD = 6) (p = 0.02). 
3.4. Adverse Events 
In the probiotic group, four participants reported an adverse event including one with stomach pain, 
two with nausea and one with diarrhea as the main adverse event. In the control group, six participants 
reported an adverse event, among which one subject reported numbness in hands and feet, one stomach 
pain and three reported having diarrhea. Only the numbness of hands and feet symptoms were scored 
severe by a physician but this was unlikely to be related to the study intervention. The other adverse 
events were rated mild or moderately. No differences were detected in biochemical or hematological 
parameters between the probiotic and control group (Table 3).  
4. Discussion  
In this randomized, controlled study, the addition of a probiotic Lactobacillus to a micronutrient 
fortified yogurt did not further substantiate the effect on the CD4 count or clinical symptoms of   
HIV-infected adults with a starting CD4 count of ≥200 cells/μL. The micronutrient fortified probiotic 
yogurt was well tolerated among the participants and was not associated with adverse events. This 
result somewhat contrasts previous studies showing a positive effect of probiotic supplementation on 
CD4 counts [21–23], but these were not performed with micronutrient supplementation which herein 
and elsewhere [17] independently can affect on CD4 count. One small RCT in Nigeria had used   
L. reuteri RC-14 in combination with the strain studied here (L. rhamnosus GR-1) [22], while the 
observational study had used L. rhamnosus GR-1 alone [23]. The RCT in Brazil had used a 
combination of different strains for children treated with ART (Bifidobacterium bifidum and 
Streptococcus thermophilus) [21]. The apparent contradiction could have two explanations. Firstly, the 
study in Nigeria [22] had found a standard deviation of the change in CD4 count of approximately  
10 cells/μL during a 4 week follow-up while in our population we found a standard 330 cells/μL 
during the same follow-up period. Because we used the previously reported standard deviation for 
sample size calculations, our study had reduced power to show an effect. The Nigerian study had 
recruited a homogenous group of women having moderate diarrhea symptoms, which could explain the Nutrients 2011, 3 
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difference in variability in CD4 counts. Secondly, our treatment period could have been too short to 
show an effect on CD4 count. Upon reflection, the use of measurements of the intestinal barrier function 
(e.g., lipo-polysaccharide or lactoferrin: mannitol ratio [6,7]), or immune activation and regulation   
(e.g., CD4+/CD25+ and FoxP3 lymphocytes [30,37]) could have served as a screening tool to assess 
potential benefits of probiotics within an HIV infected population. Therefore, we suggest these 
markers to be used in future studies to screen or assess the potential effect of specific probiotic strains. 
The overall change in CD4 count of a mean −70 cells/μL (CI 95%; −157 to −30) was lower than 
normally observed among HIV patients [38,39]. The decrease among both groups was not expected as 
the micronutrient formula tested by Kaiser et al. [17], on which our micronutrient formula was based, 
had shown an increase in CD4 count. The nutrient formula used in this study was not intended to 
provide a high dose of micronutrients at multiple times of the Dietary Reference Intake (DRI) [15,17], 
but rather an excellent dietary source at 25% of the DRI [40] to an already nutritious food (yogurt). 
The decrease in CD4 count may be explained by a tendency of parameters to decline when selected 
above a specific value (i.e., regression to the mean). Since HIV patients were included only with a 
CD4 count ≥200 cells/μL, a greater decline in CD4 count could have been observed than within an 
unselected population. This explanation is supported by the finding that participants with a CD4 count 
≥350 cells/μL at baseline experienced decrease (−187 cells/μL) while those with a CD4 count of   
<350 cells/μL experience an increase in CD4 count (67 cells/μL). The impact of this mechanism on the 
results was assessed by adjusting for baseline CD4 count levels; this adjustment did not significantly 
change the inferences of the study, and is therefore likely to be modest. The decrease might further be 
explained in part by the fact that almost half of the participants had anemia, which has been observed 
to be factors for enhanced HIV progression [41]. Again, it is easy in hindsight to consider how better 
the study could have been set up, but clearly lessons have been learned that even with limited 
resources, attempts to identify potential responders to the treatment should be made [41]. In addition, 
future studies of longer duration should be performed to assess whether benefits take longer to accrue.  
5. Conclusions  
In conclusion, the addition of a probiotic strain to a yogurt already supplemented with 
micronutrients was well tolerated by people living with HIV with a CD4 count ≥200 cells/μL, but was 
not associated with further preservation of the immune-function over a one month period. The fact that 
a yogurt could be made in a community kitchen that is acceptable in terms of taste and texture, and 
contains a complex mixture of nutritional supplements, offers some hope that grass root,   
nutrition-based approaches can potentially be found that contribute to the quality of life of people 
living with HIV. 
Acknowledgments 
We would like to sincerely thank our Tanzanian partners Judith Charles, Wilkister Karoko,   
Flora Masanja, Oswald Kaswamila, Julius Mngara, George Ogweno, Aura Andreassen, and   
Simon Buhalata for their expert assistance and hard work during the conduct of this study. We 
appreciate the dedication and excellent contribution of our Canadian team of Lesley Carmichael, Tara 
Koyama, Simon Lam, Kate Crowley and Wayne Miller and we acknowledge some financial support of Nutrients 2011, 3 
 
 
906
AFMnet Canada towards the conduct of this study. Lastly, we wish to thank the staff and volunteers of 
the Western Heads East initiative of the University of Western Ontario for providing the inspiration 
and infrastructure which made this study possible. 
Conflict of Interest 
G.R. no longer owns patents of L. rhamnosus GR-1 which cover uro-genital applications, and 
neither he nor any of the other authors have any conflicts of interest. 
References 
1.  Beach, R.; Mantero-Atienza, E.; Shor-Posner, G. Specific nutrient abnormalities in asymptomatic 
HIV-1 infection. AIDS 1992, 6, 701–708. 
2.  Tang, A.; Graham, N.; Saah, A. Effects of micronutrient intake on survival in human 
immunodeficiency virus type 1 infection. Am. J. Epidemiol. 1996, 143, 1244–1256. 
3.  Semba, R.D.; Graham, N.M.; Caiaffa, W.T.; Margolick, J.B.; Clement, L.; Vlahov, D. Increased 
mortality associated with vitamin A deficiency during human immunodeficiency virus type 1 
infection. Arch. Intern. Med. 1993, 153, 2149–2154. 
4.  Mehandru, S.; Poles, M.A.; Tenner-Racz, K.; Horowitz, A.; Hurley, A.; Hogan, C.; Boden, D.; 
Racz, P.; Markowitz, M. Primary HIV-1 infection is associated with preferential depletion   
of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200, 
761–770. 
5.  Lim, S.G.; Condez, A.; Lee, C.A.; Johnson, M.A.; Elia, C.; Poulter, L.W. Loss of mucosal CD4 
lymphocytes is an early feature of HIV infection. Clin. Exp. Immunol. 1993, 92, 448–454. 
6.  Brenchley, J.M.; Price, D.A.; Schacker, T.W.; Asher, T.E.; Silvestri, G.; Rao, S.; Kazzaz, Z.; 
Bornstein, E.; Lambotte, O.; Altmann, D.; et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat. Med. 2006, 12, 1365–1371. 
7.  Wallet, M.A.; Rodriguez, C.A.; Yin, L.; Saporta, S.; Chinratanapisit, S.; Hou, W.; Sleasman, J.W.; 
Goodenow, M.M. Microbial translocation induces persistent macrophage activation unrelated to 
HIV-1 levels or T-cell activation following therapy. AIDS 2010, 24, 1281–1290. 
8.  Gori, A.; Tincati, C.; Rizzardini, G.; Torti, C.; Quirino, T.; Haarman, M.; Ben Amor, K.;   
van Schaik, J.; Vriesema, A.; Knol, J.; et al. Early impairment of gut function and gut flora 
supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus 
pathogenesis. J. Clin. Microbiol. 2008, 46, 757–758. 
9.  Wolf, B.W.; Wheeler, K.B.; Ataya, D.G.; Garleb, K.A. Safety and tolerance of   
Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency 
virus. Food Chem. Toxicol. 1998, 36, 1085–1094. 
10.  Kelly, P.; Todd, J.; Sianongo, S.; Mwansa, J.; Sinsungwe, H.; Katubulushi, M.; Farthing, M.J.; 
Feldman, R.A. Susceptibility to intestinal infection and diarrhoea in Zambian adults in relation to 
HIV status and CD4 count. BMC Gastroenterol. 2009, 9, 7. 
11.  Cassol, E.; Malfeld, S.; Mahasha, P.; van der Merwe, S.; Cassol, S.; Seebregts, C.; Alfano, M.; 
Poli, G.; Rossouw, T. Persistent microbial translocation and immune activation in HIV-1-infected 
South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 2010, 202, 723–733. Nutrients 2011, 3 
 
 
907
12. Hummelen, R.; Hemsworth, J.; Reid, G. Micronutrients, N-Acetyl cysteine, probiotics and 
prebiotics, a review of effectiveness in reducing HIV progression. Nutrients 2010, 2, 626–651. 
13. Kanter, A.S.; Spencer, D.C.; Steinberg, M.H.; Soltysik, R.; Yarnold, P.R.; Graham, N.M. 
Supplemental vitamin B and progression to AIDS and death in black South African patients 
infected with HIV. J. Acquir. Immune Defic. Syndr. 1999, 21, 252–253. 
14. Fawzi, W.W.; Msamanga, G.I.; Spiegelman, D.; Urassa, E.J.; McGrath, N.; Mwakagile, D.; 
Antelman, G.; Mbise, R.; Herrera, G.; Kapiga, S.; et al. Randomised trial of effects of vitamin 
supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. 
Lancet 1998, 351, 1477–1482. 
15.  Fawzi, W.W.; Msamanga, G.I.; Spiegelman, D.; Wei, R.; Kapiga, S.; Villamor, E.; Mwakagile, D.; 
Mugusi, F.; Hertzmark, E.; Essex, M.; et al. A randomized trial of multivitamin supplements and 
HIV disease progression and mortality. N. Engl. J. Med. 2004, 351, 23–32. 
16.  Jiamton, S.; Pepin, J.; Suttent, R. A randomized trial of the impact of multiple micronutrient 
supplementation on mortality among HIV-infected individuals living in Bangkok. AIDS 2003, 17, 
2461–2469. 
17.  Kaiser, J.D.; Adriana, M.C.; Ondercin, J.P.; Gifford, S.L.; Pless, R.F.; Baum, M.K. Micronutrient 
supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral 
therapy: A prospective, double-blinded, placebo-controlled trial. J. Acquir. Immune Defic. Syndr. 
2006, 42, 523–528. 
18.  Kelly, P.; Shawa, T.; Mwanamakondo, S.; Soko, R.; Smith, G.; Barclay, G.R.; Sanderson, I.R. 
Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of 
micronutrient supplementation during a randomised controlled trial. BMC Gastroenterol. 2010, 
10, 72. 
19.  Fawzi, W.; Msamanga, G.; Spiegelman, D. Randomized trial of effects of vitamin supplements on 
pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998, 351, 
1477–1482. 
20. WHO/FAO.  Evaluation of Health and Nutritional Properties of Powder Milk and Live Lactic 
Acid Bacteria; Food and Agriculture Organization of the United Nations and World Health 
Organization Expert Consultation Report: Cordoba, Argentina, 2001. 
21.  Trois, L.; Cardoso, E.M.; Miura, E. Use of probiotics in HIV-infected children: a randomized 
double-blind controlled study. J. Trop. Pediatr. 2008, 54, 19–24. 
22. Anukam, K.C.; Osazuwa, E.O.; Osadolor, H.B.; Bruce, A.W.; Reid, G. Yogurt containing 
probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea 
and increases CD4 count in HIV/AIDS patients. J. Clin. Gastroenterol. 2008, 42, 239–243. 
23. Irvine, S.L.; Hummelen, R.; Hekmat, S.; Looman, C.W.; Habbema, J.D.; Reid, G. Probiotic 
yogurt consumption is associated with an increase of CD4 count among people living with 
HIV/AIDS. J. Clin. Gastroenterol. 2010, 44, 201–205. 
24. Rosenfeldt, V.; Benfeldt, E.; Valerius, N.H.; Paerregaard, A.; Michaelsen, K.F. Effect of 
probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic 
dermatitis. J. Pediatr. 2004, 145, 612–616. Nutrients 2011, 3 
 
 
908
25. Luyer,  M.D.; Buurman, W.A.; Hadfoune, M.; Speelmans, G.; Knol, J.; Jacobs, J.A.; Dejong, C.H.; 
Vriesema, A.J.; Greve, J.W. Strain-specific effects of probiotics on gut barrier integrity following 
hemorrhagic shock. Infect. Immun. 2005, 73, 3686–3692. 
26.  Braat, H.; van den Brande, J.; van Tol, E.; Hommes, D.; Peppelenbosch, M.; van Deventer, S. 
Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via 
modulation of dendritic cell function. Am. J. Clin. Nutr. 2004, 80, 1618–1625. 
27. Giamarellos-Bourboulis, E.J.; Bengmark, S.; Kanellakopoulou, K.; Kotzampassi, K. Pro- and 
synbiotics to control inflammation and infection in patients with multiple injuries. J. Trauma 
2009, 67, 815–821. 
28.  Allen, S.J.; Martinez, E.G.; Gregorio, G.V.; Dans, L.F. Probiotics for treating acute infectious 
diarrhoea. Cochrane Database Syst. Rev. 2010, CD003048; doi:10.1002/14651858.CD003048.pub3. 
29. Hummelen, R.; Vos, A.P.; van’t Land, B.; van Norren, K.; Reid, G. Altered host-microbe 
interaction in HIV: a target for intervention with pro- and prebiotics. Int. Rev. Immunol. 2010, 29, 
485–513. 
30.  UNAIDS. MDG6: six things you need to know about the AIDS response today. Available online: 
http://data.unaids.org/pub/Report/2010/20100917_mdg6_report_en.pdf (accessed on 1 October 2010). 
31.  Wenner, M. A cultured response to HIV. Nat. Med. 2009, 15, 594–597. 
32. Reid, G.; Charbonneau, D.; Gonzalez, S.; Gardiner, G.; Erb, J.; Bruce, A.W. Ability of 
Lactobacillus GR-1 and RC-14 to stimulate host defences and reduce gut translocation and 
infectivity of Salmonella typhimurium. Nutraceut Food 2002, 7, 168–173. 
33.  Baroja, M.L.; Kirjavainen, P.V.; Hekmat, S.; Reid, G. Anti-inflammatory effects of probiotic 
yogurt in inflammatory bowel disease patients. Clin. Exp. Immunol. 2007, 149, 470–479. 
34. Ministry of Health, United Republic of Tanzania, National Guidelines for the Clinical 
Management of HIV/AIDS, 2005. Available online: http://www.collections.infocollections.org/ 
whocountry/en/d/Js6885e/15.3.1.html (accessed on 28 September 2010).  
35.  WHO. Diarrhoeal disease Factsheet No 330, August 2009. Available online: http://www.who.int/ 
mediacentre/factsheets/fs330/en/index.html (accessed on 1 October 2010). 
36. Hekmat, S.; Soltani, H.; Reid, G. Growth and survival of Lactobacillus reuteri RC-14 and 
Lactobacillus rhamnosus GR-1 in yogurt for use as a functional food. Food Sci. Emerg. Technol. 
2009, 10, 293–296. 
37. van’t Land, B.; Benlhassan-Chahour, K.; Rizzardini, G.; Vriesema, A.; Garssen, J.; Trabattoni, D.; 
Bray, D.; Gori, A.; Clerici, M. A specific mixture of prebiotic oligosaccharides reduces   
hyper-immune activation and improves NK cell cytolytic activity in HAART-naive HIV positive 
adults. In Proceedings of 15th Conference on Retroviruses and Opportunistic Infections (CROI), 
Boston, MA, USA, 3–6 February 2008. 
38. Mermin, J.; Lule, J.; Ekwaru, J.P.; Malamba, S.; Downing, R.; Ransom, R.; Kaharuza, F.;   
Culver, D.; Kizito, F.; Bunnell, R.; et al. Effect of co-trimoxazole prophylaxis on morbidity, 
mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364, 
1428–1434. Nutrients 2011, 3 
 
 
909
39. Holmes, C.; Wood, R.; Badri, M.; Zilber, S.; Wang, B.; Maartens, G.; Zheng, H.; Lu, Z.; 
Freedberg, K.; Losina, E. CD4 Decline and incidence of opportunistic infections in Cape Town, 
South Africa: implications for prophylaxis and treatment. J. Acquir. Immune Defic. Syndr. 2006, 
42, 464–469. 
40.  Dietary Reference Intakes: The Essential Guide to Nutrient Requirements; Otten, J.J.,   
Hellwig, J.P., Meyers, L.D., Eds.; National Academy of Sciences: Washington, DC, USA, 2006. 
41.  O’Brien, M.E.; Kupka, R.; Msamanga, G.I.; Saathoff, E.; Hunter, D.J.; Fawzi, W.W. Anemia is 
an independent predictor of mortality and immunologic progression of disease among women 
with HIV in Tanzania. J. Acquir. Immune Defic. Syndr. 2005, 40, 219–225. 
© 2011 by the authors, licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http,//creativecommons.org/licenses/by/3.0/). 